Tor Olofsson
1 – 10 of 29
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
(
- Contribution to journal › Article
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
(
- Contribution to journal › Article
-
Mark
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA) : A Retrospective Observational Study
(
- Contribution to journal › Article
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
- 2021
-
Mark
Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis : results from the randomised controlled SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study
(
- Contribution to journal › Article
-
Mark
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter?
(
- Contribution to journal › Article